LncRNA AFAP1-AS1 Induces Gefitinib Resistance of Lung Adenocarcinoma Through the miR-653-5p/AGR2 Axis

References

• Sung H, Ferlay J, Siegel RL., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Sun GZ, Zhao TW. Lung adenocarcinoma pathology stages related gene identification. Math Biosci Eng. 2019;17(1):737–746. doi:10.3934/mbe.2020038
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen Z, Chen R, et al. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer. Future Oncol. 2022;18(14):1757–1775. doi:10.2217/fon-2021-0862
   PubMed Web of Science ®Google Scholar
• Sini C, Tuzi A, Rossi G, Russo A, Pezzuto A. Acquired resistance in oncogene-addicted non-small-cell lung cancer. Future Oncol. 2018;14(13s):29–40. doi:10.2217/fon-2018-0097
   PubMedGoogle Scholar
• Noronha V, Patil VM, Joshi A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 2020;38(2):124–136. doi:10.1200/JCO.19.01154
   PubMed Web of Science ®Google Scholar
• Hosomi Y, Morita S, Sugawara S, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol. 2020;38(2):115–123. doi:10.1200/JCO.19.01488
   PubMed Web of Science ®Google Scholar
• Mok TS, Cheng Y, Zhou X, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018;36(22):2244–2250. doi:10.1200/JCO.2018.78.7994
   PubMed Web of Science ®Google Scholar
• Liao BC, Griesing S, Yang JC. Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients. Ther Adv Med Oncol. 2019;11:1758835919890286. doi:10.1177/1758835919890286
   Web of Science ®Google Scholar
• Yang JJ, Fang J, Shu YQ, et al. A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer. Invest New Drugs. 2021;39(2):477–487. doi:10.1007/s10637-020-01010-4
   PubMed Web of Science ®Google Scholar
• Titmarsh HF, O’Connor R, Dhaliwal K, Akram AR. Corrigendum: the emerging role of the c-MET-HGF axis in non-small cell lung cancer tumor immunology and immunotherapy. Front Oncol. 2020;10:1516. doi:10.3389/fonc.2020.01516
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139. doi:10.1056/NEJMoa040938
   PubMed Web of Science ®Google Scholar
• Jarroux J, Morillon A, Pinskaya M. History, discovery, and classification of lncRNAs. Adv Exp Med Biol. 2017;1008:1–46. doi:10.1007/978-981-10-5203-3_1
   PubMed Web of Science ®Google Scholar
• Puvvula PK. LncRNAs regulatory networks in cellular senescence. Int J Mol Sci. 2019;20:11. doi:10.3390/ijms20112615
   Web of Science ®Google Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–3981. doi:10.1158/0008-5472.CAN-16-2634
   PubMed Web of Science ®Google Scholar
• Feng C, Zhao Y, Li Y, Zhang T, Ma Y, Liu Y. LncRNA MALAT1 promotes lung cancer proliferation and gefitinib resistance by acting as a miR-200a sponge. Arch Bronconeumol. 2019;55(12):627–633. doi:10.1016/j.arbr.2019.03.018
   PubMed Web of Science ®Google Scholar
• Lei Y, Guo W, Chen B, Chen L, Gong J, Li W. Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer. Oncol Rep. 2018;40(6):3438–3446. doi:10.3892/or.2018.6762
   PubMed Web of Science ®Google Scholar
• Yu T, Bai W, Su Y, Wang Y, Wang M, Ling C. Enhanced expression of lncRNA ZXF1 promotes cisplatin resistance in lung cancer cell via MAPK axis. Exp Mol Pathol. 2020;116:104484. doi:10.1016/j.yexmp.2020.104484
   PubMed Web of Science ®Google Scholar
• Huang N, Guo W, Ren K, et al. LncRNA AFAP1-AS1 Supresses miR-139-5p and promotes cell proliferation and chemotherapy resistance of non-small cell lung cancer by competitively upregulating RRM2. Front Oncol. 2019;9:1103. doi:10.3389/fonc.2019.01103
   PubMed Web of Science ®Google Scholar
• Leng W, Liu Q, Zhang S, Sun D, Guo Y. LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis. Cancer Biol Ther. 2020;21(11):1072–1080. doi:10.1080/15384047.2020.1829266
   PubMed Web of Science ®Google Scholar
• Han M, Gu Y, Lu P, et al. Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation. Mol Cancer. 2020;19(1):26. doi:10.1186/s12943-020-1145-5
   PubMed Web of Science ®Google Scholar
• Robinson EK, Covarrubias S, Carpenter S. The how and why of lncRNA function: an innate immune perspective. Biochim Biophys Acta - Gene Regul Mech. 2020;1863(4):194419. doi:10.1016/j.bbagrm.2019.194419
   PubMed Web of Science ®Google Scholar
• Sun J, Min H, Yu L, Yu G, Shi Y, Sun J. The knockdown of LncRNA AFAP1-AS1 suppressed cell proliferation, migration, and invasion, and promoted apoptosis by regulating miR-545-3p/hepatoma-derived growth factor axis in lung cancer. Anticancer Drugs. 2021;32(1):11–21. doi:10.1097/CAD.0000000000001003
   PubMed Web of Science ®Google Scholar
• Chi R, Chen X, Liu M, et al. Role of SNHG7-miR-653-5p-STAT2 feedback loop in regulating neuroblastoma progression. J Cell Physiol. 2019;234(8):13403–13412. doi:10.1002/jcp.28017
   PubMed Web of Science ®Google Scholar
• Lian LP, Xi XY. Long non-coding RNA XIST protects chondrocytes ATDC5 and CHON-001 from IL-1β-induced injury via regulating miR-653-5p/SIRT1 axis. J Biol Regul Homeost Agents. 2020;34(2):379–391. doi:10.23812/19-549-A-65
   PubMed Web of Science ®Google Scholar
• Liu F, Hu L, Pei Y, et al. Long non-coding RNA AFAP1-AS1 accelerates the progression of melanoma by targeting miR-653-5p/RAI14 axis. BMC Cancer. 2020;20(1):258. doi:10.1186/s12885-020-6665-2
   PubMed Web of Science ®Google Scholar
• Han W, Wang L, Zhang L, Wang Y, Li Y. Circular RNA circ-RAD23B promotes cell growth and invasion by miR-593-3p/CCND2 and miR-653-5p/TIAM1 pathways in non-small cell lung cancer. Biochem Biophys Res Commun. 2019;510(3):462–466. doi:10.1016/j.bbrc.2019.01.131
   PubMed Web of Science ®Google Scholar
• Obacz J, Takacova M, Brychtova V, et al. The role of AGR2 and AGR3 in cancer: similar but not identical. Eur J Cell Biol. 2015;94(3–4):139–147. doi:10.1016/j.ejcb.2015.01.002
   PubMed Web of Science ®Google Scholar
• Moidu NA, Ns AR, Syafruddin SE, Low TY, Mohtar MA. Secretion of pro-oncogenic AGR2 protein in cancer. Heliyon. 2020;6(9):e05000. doi:10.1016/j.heliyon.2020.e05000
   PubMed Web of Science ®Google Scholar
• Tian S, Hu J, Tao K, et al. Secreted AGR2 promotes invasion of colorectal cancer cells via Wnt11-mediated non-canonical Wnt signaling. Exp Cell Res. 2018;364(2):198–207. doi:10.1016/j.yexcr.2018.02.004
   PubMed Web of Science ®Google Scholar
• Alavi M, Mah V, Maresh EL, et al. High expression of AGR2 in lung cancer is predictive of poor survival. BMC Cancer. 2015;15:655. doi:10.1186/s12885-015-1658-2
   PubMed Web of Science ®Google Scholar
• Xue X, Fei X, Hou W, Zhang Y, Liu L, Hu R. miR-342-3p suppresses cell proliferation and migration by targeting AGR2 in non-small cell lung cancer. Cancer Lett. 2018;412:170–178. doi:10.1016/j.canlet.2017.10.024
   PubMed Web of Science ®Google Scholar
• Luu TT, Bach DH, Kim D, Hu R, Park HJ, Lee SK. Overexpression of AGR2 Is associated with drug resistance in mutant non-small cell lung cancers. Anticancer Res. 2020;40(4):1855–1866. doi:10.21873/anticanres.14139
   PubMed Web of Science ®Google Scholar
• Huang Z, Ma Y, Zhang P, Si J, Xiong Y, Yang Y. Long non-coding RNA H19 confers resistance to gefitinib via miR-148b-3p/DDAH1 axis in lung adenocarcinoma. Anticancer Drugs. 2020;31(1):44–54. doi:10.1097/CAD.0000000000000831
   PubMed Web of Science ®Google Scholar
• He S, Shi J, Zhou H, Li Q, Wu L. Lnc-ABCA12-8 confers acquired resistance to gefitinib in non-small cell lung cancer by regulating the alternative splicing of fibronectin 1 in the IIICS region. Cancer Gene Ther. 2022;29:1686–1696. doi:10.1038/s41417-022-00483-0
   PubMed Web of Science ®Google Scholar
• Bi Z, Li Q, Dinglin X, et al. Nanoparticles (NPs)-Meditated LncRNA AFAP1-AS1 silencing to block Wnt/β-catenin signaling pathway for synergistic reversal of radioresistance and effective cancer radiotherapy. Adv Sci. 2020;7(18):2000915. doi:10.1002/advs.202000915
   Web of Science ®Google Scholar
• Liu Y, Hu Q, Wang X. AFAP1-AS1 induces cisplatin resistance in non-small cell lung cancer through PI3K/AKT pathway. Oncol Lett. 2020;19(1):1024–1030. doi:10.3892/ol.2019.11175
   PubMed Web of Science ®Google Scholar
• Fu Q, Sun Z, Yang F, Mao T, Gao Y, Wang H. SOX30, a target gene of miR-653-5p, represses the proliferation and invasion of prostate cancer cells through inhibition of Wnt/β-catenin signaling. Cell Mol Biol Lett. 2019;24:71. doi:10.1186/s11658-019-0195-4
   PubMed Web of Science ®Google Scholar
• Zhang M, Wang H, Zhang X, Liu F. miR‑653‑5p suppresses the growth and migration of breast cancer cells by targeting MAPK6. Mol Med Rep. 2021;23:3. doi:10.3892/mmr.2020.11641
   PubMed Web of Science ®Google Scholar
• Gong W, Ekmu B, Wang X, Lu Y, Wan L. AGR2-induced glucose metabolism facilitated the progression of endometrial carcinoma via enhancing the MUC1/HIF-1α pathway. Hum Cell. 2020;33(3):790–800. doi:10.1007/s13577-020-00356-4
   PubMed Web of Science ®Google Scholar
• Sommerova L, Ondrouskova E, Martisova A, Zoumpourlis V, Galtsidis S, Hrstka R. ZEB1/miR-200c/AGR2: a new regulatory loop modulating the epithelial-mesenchymal transition in lung adenocarcinomas. Cancers. 2020;12:6. doi:10.3390/cancers12061614
   Web of Science ®Google Scholar